{"id":46537,"date":"2019-01-31T18:57:08","date_gmt":"2019-01-31T17:57:08","guid":{"rendered":"https:\/\/rtvnp.rs\/?p=46537"},"modified":"2019-01-31T18:57:08","modified_gmt":"2019-01-31T17:57:08","slug":"stize-antibiotik-protiv-raka-prvi-potpuni-lijek-za-opaku-bolest","status":"publish","type":"post","link":"https:\/\/arhiva.rtvnp.rs\/?p=46537","title":{"rendered":"STI\u017dE ANTIBIOTIK PROTIV RAKA, PRVI POTPUNI LIJEK ZA OPAKU BOLEST"},"content":{"rendered":"<p>Tim nau\u010dnika objavio je da \u0107e za godinu imati prvi &#8220;potpuni lijek&#8221; za rak. I ne samo to, tvrde da \u0107e terapija biti kratka, jeftina i u\u010dinkovita te da ne\u0107e imati nuspojave ili \u0107e one biti minimalne.<\/p>\n<p>Lijek je nazvan &#8220;MuTaTo&#8221; (multi-target toxin), a istra\u017eiva\u010di ka\u017eu da se u su\u0161tini mo\u017ee smatrati antibiotikom protiv raka jer posjeduje tehnologiju &#8220;ometanja rasta zlo\u0107udnih \u0107elija na najvi\u0161em nivou&#8221;.<\/p>\n<p>Ova nevjerovatna novost u lije\u010denju raka dolazi iz izraelske kompanije &#8220;Accelerated Evolution Biotechnologies Ltd.&#8221;, osnovane 2000. godine.<\/p>\n<p>Hayat<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tim nau\u010dnika objavio je da \u0107e za godinu imati prvi &#8220;potpuni lijek&#8221; za rak. I ne samo to, tvrde da \u0107e terapija biti kratka, jeftina i u\u010dinkovita te da ne\u0107e imati nuspojave ili \u0107e one biti minimalne. Lijek je nazvan &#8220;MuTaTo&#8221; (multi-target toxin), a istra\u017eiva\u010di ka\u017eu da se u su\u0161tini mo\u017ee smatrati antibiotikom protiv raka [&hellip;]<\/p>\n","protected":false},"author":21,"featured_media":46538,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[],"class_list":["post-46537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-reportaze"],"_links":{"self":[{"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=\/wp\/v2\/posts\/46537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46537"}],"version-history":[{"count":0,"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=\/wp\/v2\/posts\/46537\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=\/wp\/v2\/media\/46538"}],"wp:attachment":[{"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/arhiva.rtvnp.rs\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}